[go: up one dir, main page]

MA33445B1 - Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies - Google Patents

Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies

Info

Publication number
MA33445B1
MA33445B1 MA34552A MA34552A MA33445B1 MA 33445 B1 MA33445 B1 MA 33445B1 MA 34552 A MA34552 A MA 34552A MA 34552 A MA34552 A MA 34552A MA 33445 B1 MA33445 B1 MA 33445B1
Authority
MA
Morocco
Prior art keywords
diseases
treatment
production
diene
hydroxy
Prior art date
Application number
MA34552A
Other languages
Arabic (ar)
English (en)
Inventor
Wolfgang Schwede
Ulrich Klar
Carsten Möller
Andrea Rotgeri
Wilhelm Bone
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33445(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA33445B1 publication Critical patent/MA33445B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés de formule (I) ayant un effet antagoniste sur la progestérone et leur procédé de production, leur utilisation pour le traitement et/ou la prophylaxie de maladies ainsi que leur utilisation pour la production de médicaments destinés au traitement et/ou à la prophylaxie de maladies, en particulier des fibromes utérins (myomes, léiomyomes utérins), de l'endométriose, des règles importantes, des méningiomes, des cancers du sein hormono-dépendants et des troubles associés à la ménopause, ou au contrôle de la fertilité et à la contraception d'urgence.
MA34552A 2009-07-20 2010-07-07 Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies MA33445B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009034362A DE102009034362A1 (de) 2009-07-20 2009-07-20 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
PCT/EP2010/004149 WO2011009531A2 (fr) 2009-07-20 2010-07-07 Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies

Publications (1)

Publication Number Publication Date
MA33445B1 true MA33445B1 (fr) 2012-07-03

Family

ID=43383964

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34552A MA33445B1 (fr) 2009-07-20 2010-07-07 Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies

Country Status (47)

Country Link
US (4) US20120149670A1 (fr)
EP (4) EP3252069B1 (fr)
JP (3) JP5795312B2 (fr)
KR (2) KR101687853B1 (fr)
CN (1) CN102482317B (fr)
AR (1) AR077491A1 (fr)
AU (1) AU2010275849B2 (fr)
BR (1) BR112012001344B8 (fr)
CA (1) CA2768407C (fr)
CL (1) CL2012000166A1 (fr)
CO (1) CO6491067A2 (fr)
CR (2) CR20170091A (fr)
CU (1) CU20120012A7 (fr)
CY (3) CY1114260T1 (fr)
DE (1) DE102009034362A1 (fr)
DK (3) DK2623510T3 (fr)
DO (2) DOP2012000015A (fr)
EA (2) EA021946B1 (fr)
EC (2) ECSP12011616A (fr)
ES (3) ES2416461T3 (fr)
GT (1) GT201200012A (fr)
HN (1) HN2012000137A (fr)
HR (3) HRP20130558T1 (fr)
HU (2) HUE043757T2 (fr)
IL (1) IL216967B (fr)
IN (1) IN2012DN00598A (fr)
JO (2) JO3009B1 (fr)
LT (2) LT3252069T (fr)
MA (1) MA33445B1 (fr)
ME (2) ME03400B (fr)
MX (2) MX2012000930A (fr)
MY (1) MY179447A (fr)
NO (1) NO2623510T3 (fr)
NZ (2) NZ623417A (fr)
PE (2) PE20170084A1 (fr)
PL (3) PL2623510T3 (fr)
PT (3) PT2623510T (fr)
RS (1) RS52811B (fr)
SG (3) SG10201811830PA (fr)
SI (3) SI2623510T1 (fr)
TN (1) TN2012000028A1 (fr)
TR (1) TR201908600T4 (fr)
TW (1) TWI505830B (fr)
UA (1) UA106502C2 (fr)
UY (1) UY32791A (fr)
WO (1) WO2011009531A2 (fr)
ZA (1) ZA201201222B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011088270A1 (de) 2011-12-12 2013-06-13 Bayer Intellectual Property Gmbh (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
SI2983671T1 (sl) * 2013-04-11 2020-06-30 Bayer Pharma Aktiengesellschaft Dozirna oblika antagonista receptorja progesterona
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
JP2018515551A (ja) 2015-05-18 2018-06-14 バイエル・ファルマ・アクティエンゲゼルシャフト 選択的プロゲステロン受容体モジュレーター（ｓｐｒｍ）レジメン
EP3214092A1 (fr) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Promédicaments du modulateur du récepteur de progesterone (sprm) (11.bêta.,17.bêta.)-17-hydroxy-11-[4-(méthylsulphonyle)phenyle]-17-(pentafluoroéthyl)estra-4,9-dièn-3-one
EP3384913A1 (fr) 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Modulateurs sélectifs du récepteur de la progestérone et niveau d' strogène stabilisé chez un patient
EP3701951A4 (fr) * 2017-10-26 2020-09-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. Forme cristalline de modulateur sélectif de récepteurs de progestérone et son procédé de préparation
EP4486364A1 (fr) 2022-03-01 2025-01-08 Altin Biosciences Corporation Compositions de crila® et d'egcg pour le traitement de fibromes

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2620707B1 (fr) 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FR2644789B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
DK0411733T3 (da) 1989-08-04 1999-06-28 Schering Ag 11-beta-aryl-gona-4,9-dien-3-oner
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
CA2100514C (fr) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma Steroides de type 17-spiromethylene
FR2718354B1 (fr) 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
DK0792152T3 (da) 1994-11-22 2004-07-12 Balance Pharmaceuticals Inc Fremgangsmåder til svangerskabsforebyggelse
ATE194358T1 (de) 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-substituierte progesteron derivate als antigestagene
WO1998005679A2 (fr) 1996-08-05 1998-02-12 Duke University Antagonistes mixtes du recepteur progesterone et techniques de dosage associees
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
AU3344099A (en) 1998-04-17 1999-11-08 Kyowa Hakko Kogyo Co. Ltd. Analgetic agent
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (fr) 2000-05-23 2001-11-28 JENAPHARM GmbH Nouveaux formes solides du mesoprogestin 11beta-(4E-(hxdroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
ATE344273T1 (de) 2000-09-18 2006-11-15 Applied Research Systems Verfahren zur herstellung von 21-hydroxy-6,19- oxidoprogesteron (21oh-6op)
DE10051609A1 (de) 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PL360151A1 (en) 2000-10-18 2004-09-06 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
PL366415A1 (en) 2000-10-18 2005-01-24 Schering Aktiengesellschaft Inhibition of the growth factor dependency of tumor cells
ES2290284T3 (es) * 2001-01-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft El uso de antigestagenos para inhibir la maduracion endometrial acelerada durante el tratamiento de infertilidad.
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DK1501859T3 (da) 2002-05-03 2006-03-06 Schering Ag 17 alfa-fluoralkyl- 11 beta-benzaldoxim-steroider, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse steroider samt deres anvendelse til fremstilling af lægemidler
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
MX2007000273A (es) 2004-07-09 2007-05-21 Population Council Inc Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona.
WO2006101009A1 (fr) 2005-03-18 2006-09-28 Hirose Engineering Co., Ltd. Compose luminescent rouge a base de rouge du nil et element luminescent l’utilisant
US20070105828A1 (en) 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (fr) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft 11beta-(4-Acetylphenyle)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-one crystalline
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20090075989A1 (en) * 2006-12-21 2009-03-19 Wolfgang Schwede Non-steroidal progesterone receptor modulators
CN101454150B (zh) 2007-03-01 2014-05-21 Prs地中海有限公司 耐uv的多层格室加固体系
EP2123279A1 (fr) 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Administration séquentielle de 20,20,21,21,21-Ppentafluor-17-hydroxy-1 1bêta-[4-(hydroxyacétyl) phényl]-19-nor-17alpha-pregna-4,9-dien-3-on et un ou plusieurs gestagènes destinés au traitement de maladies gynécologiques
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
SI3252069T1 (sl) 2019-06-28
PT2432798E (pt) 2013-06-28
SG10201811830PA (en) 2019-02-27
DOP2012000015A (es) 2016-04-15
EP3252069A1 (fr) 2017-12-06
US20150342962A1 (en) 2015-12-03
PL2623510T3 (pl) 2018-02-28
GT201200012A (es) 2013-10-15
HN2012000137A (es) 2015-05-04
CY1119661T1 (el) 2018-04-04
HRP20191049T1 (hr) 2019-09-20
HK1171456A1 (en) 2013-03-28
EP2623510B1 (fr) 2017-08-23
AU2010275849B2 (en) 2014-12-18
CU20120012A7 (es) 2012-07-31
EP2432798B1 (fr) 2013-04-03
US20120094969A1 (en) 2012-04-19
SG10201404159VA (en) 2014-10-30
HUE037339T2 (hu) 2018-08-28
HRP20171805T1 (hr) 2017-12-29
LT3252069T (lt) 2019-06-10
IN2012DN00598A (fr) 2015-06-12
ZA201201222B (en) 2022-11-30
AR077491A1 (es) 2011-08-31
KR20120046182A (ko) 2012-05-09
CN102482317B (zh) 2014-09-17
CR20120040A (es) 2012-03-12
HRP20130558T1 (hr) 2013-07-31
EA201301263A1 (ru) 2014-08-29
JP6130087B1 (ja) 2017-05-17
ECSP18047708A (es) 2018-06-30
ME03400B (fr) 2020-01-20
BR112012001344B1 (pt) 2020-09-24
ES2648292T3 (es) 2017-12-29
DE102009034362A1 (de) 2011-01-27
UA106502C2 (uk) 2014-09-10
UY32791A (es) 2011-02-28
PT3252069T (pt) 2019-06-18
SG177519A1 (en) 2012-02-28
CY1114260T1 (el) 2016-08-31
KR101854059B1 (ko) 2018-05-02
AU2010275849A1 (en) 2012-02-02
EP3272763A1 (fr) 2018-01-24
CN102482317A (zh) 2012-05-30
ES2416461T3 (es) 2013-08-01
US10155004B2 (en) 2018-12-18
PL3252069T3 (pl) 2019-09-30
EP2432798A2 (fr) 2012-03-28
EP3252069B1 (fr) 2019-04-03
PE20170084A1 (es) 2017-03-30
LT2623510T (lt) 2017-12-11
US9717739B2 (en) 2017-08-01
PE20121085A1 (es) 2012-08-04
DK2432798T3 (da) 2013-07-01
EA201200121A1 (ru) 2012-07-30
JO3009B1 (ar) 2016-09-05
TWI505830B (zh) 2015-11-01
SI2623510T1 (sl) 2017-12-29
ECSP12011616A (es) 2012-02-29
ME01534B (me) 2014-04-20
BR112012001344B8 (pt) 2021-05-25
MY179447A (en) 2020-11-06
NO2623510T3 (fr) 2018-01-20
EA021946B1 (ru) 2015-10-30
TW201105331A (en) 2011-02-16
WO2011009531A3 (fr) 2011-04-28
NZ597639A (en) 2014-04-30
EP2623510A1 (fr) 2013-08-07
US20170202857A1 (en) 2017-07-20
WO2011009531A2 (fr) 2011-01-27
TR201908600T4 (tr) 2019-07-22
CR20170091A (es) 2018-02-06
TN2012000028A1 (en) 2013-09-19
CA2768407A1 (fr) 2011-01-27
JP2015178522A (ja) 2015-10-08
MX338217B (es) 2016-04-07
ES2730209T3 (es) 2019-11-08
MX2012000930A (es) 2012-03-26
IL216967B (en) 2018-06-28
BR112012001344A2 (pt) 2016-03-15
SI2432798T1 (sl) 2013-08-30
US8278469B2 (en) 2012-10-02
KR20160093110A (ko) 2016-08-05
JP2012533575A (ja) 2012-12-27
NZ623417A (en) 2015-10-30
EA025150B1 (ru) 2016-11-30
CU24080B1 (fr) 2015-03-30
PT2623510T (pt) 2017-11-24
CY1121926T1 (el) 2020-10-14
CA2768407C (fr) 2017-10-24
DK3252069T3 (da) 2019-06-24
JO3732B1 (ar) 2021-01-31
PL2432798T3 (pl) 2013-08-30
DK2623510T3 (en) 2017-12-04
CL2012000166A1 (es) 2012-08-31
RS52811B (sr) 2013-10-31
DOP2015000276A (es) 2018-04-15
US20120149670A1 (en) 2012-06-14
HUE043757T2 (hu) 2019-09-30
JP2017105813A (ja) 2017-06-15
KR101687853B1 (ko) 2016-12-19
CO6491067A2 (es) 2012-07-31
IL216967A0 (en) 2012-02-29
JP5795312B2 (ja) 2015-10-14

Similar Documents

Publication Publication Date Title
MA33445B1 (fr) Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
Lima et al. Effective treatment of vaginal atrophy with isoflavone vaginal gel
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA34099B1 (fr) Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose
MA35237B1 (fr) Anticorps neutralisant le récepteur de la prolactine mat3 et usage thérapeutique associé
MA28436B1 (fr) Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine
WO2011009534A3 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-aryle, procédés de préparation et utilisation pour le traitement de maladies
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA32997B1 (fr) Macrolide anti-inflammatoire
MA38465A1 (fr) Forme posologique de l'antagoniste du récepteur de la progestérone
UA59389U (ru) Способ лечения гиперпластических процессов матки
BR112015001479A2 (pt) aperfeiçoamento de excitação sexual, desejo sexual, orgasmo e/ou prazer após administração de prasterona intravaginal (dhea) em mulheres que não sofrem ou independente de dispareunia ou outros sintomas de atrofia vulvo-vaginal
MA37836A1 (fr) Antagonistes du récepteur 5-ht3
MA38455B1 (fr) Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin
TH85420B (th) การใช้สารปรับโพรเจสเตอโรนรีเซปเตอร์ชนิดนอน-สเตียรอยด์